These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36697132)

  • 1. Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors.
    Eworuke E; Welch EC; Haug N; Horgan C; Lee HS; Zhao Y; Huang TY
    J Am Coll Cardiol; 2023 Jan; 81(4):321-331. PubMed ID: 36697132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
    Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
    Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
    Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
    BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy.
    Sica DA; Black HR
    Congest Heart Fail; 2002; 8(6):334-41, 345. PubMed ID: 12461324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study.
    Rim MY; Ro H; Kang WC; Kim AJ; Park H; Chang JH; Lee HH; Chung W; Jung JY
    Am J Kidney Dis; 2012 Oct; 60(4):576-82. PubMed ID: 22658321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
    Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
    J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema.
    Maroteau C; Siddiqui MK; Veluchamy A; Carr F; White M; Cassidy AJ; Baranova EV; Rasmussen ER; Eriksson N; Bloch KM; Brown NJ; Bygum A; Hallberg P; Karawajczyk M; Magnusson PKE; Yue QY; Syvänen AC; von Buchwald C; Alfirevic A; Maitland-van der Zee AH; Wadelius M; Palmer CNA;
    Clin Pharmacol Ther; 2020 Dec; 108(6):1195-1202. PubMed ID: 32496628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.
    Tan NY; Deng Y; Yao X; Sangaralingham LR; Shah ND; Rule AD; Burnett JC; Dunlay SM; Sangaralingham SJ
    Mayo Clin Proc Innov Qual Outcomes; 2021 Apr; 5(2):286-297. PubMed ID: 33997628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
    Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
    Shi V; Senni M; Streefkerk H; Modgill V; Zhou W; Kaplan A
    Int J Cardiol; 2018 Aug; 264():118-123. PubMed ID: 29776559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sacubitril/valsartan in heart failure compared to renin-angiotensin-aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials.
    Hernandez AV; Pasupuleti V; Scarpelli N; Malespini J; Banach M; Bielecka-Dabrowa AM
    Arch Med Sci; 2023; 19(3):565-576. PubMed ID: 37313196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis.
    Elhence H; Dodge JL; Lee BP
    Clin Gastroenterol Hepatol; 2024 Feb; 22(2):315-323.e17. PubMed ID: 37495200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE inhibitor-mediated angioedema.
    Montinaro V; Cicardi M
    Int Immunopharmacol; 2020 Jan; 78():106081. PubMed ID: 31835086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preadmission use of renin-angiotensin blockers and rupture of abdominal aortic aneurysm: a nationwide, population-based study.
    Wemmelund H; Høgh A; Hundborg HH; Johnsen SP; Lindholt JS
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):141-50. PubMed ID: 26817783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Sacubitril/Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction during the Vulnerable Phase: A Multicenter, Assessor-Blinded, Prospective, Observational, Cohort Study.
    He Y; Lu X; Zheng Y; Song M; Shen B; Nienaber CA; Chen G; Wu F; Zheng J; Zhang W; Wang Y; Li X; Wen H; Yu X; Zhou Y
    Cardiology; 2021; 146(3):335-344. PubMed ID: 33780933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink.
    Mahmoudpour SH; Baranova EV; Souverein PC; Asselbergs FW; de Boer A; Maitland-van der Zee AH;
    Br J Clin Pharmacol; 2016 Dec; 82(6):1647-1659. PubMed ID: 27524468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the withdrawal of renin-angiotensin-aldosterone inhibitors on mortality in COVID-19 patients.
    Caro-Codón J; Rey JR; Iniesta AM; Rosillo SO; Castrejon-Castrejon S; Rodriguez-Sotelo L; Garcia-Veas JM; Marco I; Martinez LA; Martin-Polo L; Merino C; Martinez-Cossiani M; Buño A; Gonzalez-Valle L; Herrero A; López-de-Sá E; Merino JL;
    Rev Port Cardiol; 2022 Oct; 41(10):823-830. PubMed ID: 35784098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.